GenSight Biologics S.A. (EPA:SIGHT)

Market Cap	28.84M
Revenue (ttm)	2.63M
Net Income (ttm)	-14.00M
Shares Out	128.18M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	240,242
Average Volume	226,760
Open	0.2240
Previous Close	0.2260
Day's Range	0.2170 - 0.2315
52-Week Range	0.2005 - 0.4960
Beta	2.14
RSI	37.89
Earnings Date	Mar 19, 2025

About GenSight Biologics

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated N...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 16
• Stock Exchange: Euronext Paris
• Ticker Symbol: SIGHT

Financial Performance

In 2024, GenSight Biologics's revenue was 2.63 million, a decrease of -11.44% compared to the previous year's 2.96 million. Losses were -14.00 million, -46.60% less than in 2023.